Nitramines (i.e., Compounds Containing Nitro Bonded Directly To Amino Nitrogen) Patents (Class 514/610)
  • Patent number: 8633228
    Abstract: A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(?G1)-Q1 (wherein G1 and G2 represent an oxygen atom or the like, Q1 represents a phenyl group which may have a substituent, a heterocyclic group which may have a substituent, or the like), or the like, Q2 represents a phenyl group or the like, G3 represents an oxygen atom or the like, and R1 and R2 each independently represent a hydrogen atom, a C1-C6 alkyl group, or a group represented by -L-D, or the like (provided that at least either R1 or R2 represents a group represented by -L-D); as an active ingredient exhibits an excellent effect.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: January 21, 2014
    Assignee: Mitsui Chemicals Agro, Inc.
    Inventors: Yumi Kobayashi, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Hidenori Daido, Yusuke Takahashi, Shinichi Banba
  • Patent number: 8193247
    Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: June 5, 2012
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Yousef Al-Abed
  • Publication number: 20110306639
    Abstract: The present invention discloses hydrocarbylidene nitrohydrozinecarboximidamides and the use thereof as well as a method for making the same. The structural general formula of the compounds are shown in formula I, wherein, R1 is C1-C10 saturated and/or unsaturated aliphatic hydrocarbonyl, benzyl, substituted benzyl, halogenated picolyl, halogenated thiazolyl methyl, tetrahydrofuryl methyl or oxazolyl methyl; R2 is hydrogen, C1-C5 saturated and/or unsaturated aliphatic hydrocarbonyl, phenyl, substituted phenyl, pyridyl or substituted pyridyl; R3 is hydrogen, C1-C10 saturated and/or unsaturated aliphatic hydrocarbonyl, furyl, phenyl, substituted phenyl, benzyl or substituted benzyl. The tests of insecticidal activity show that the hydrocarbylidene nitrohydrozinecarboximidamides shown by formula (I) have high preventive efficiency against insect pests of plants, such as aphid, plant hopper, cotton bollworm, asparagus caterpillar, and the like, and can be used as plant insecticides.
    Type: Application
    Filed: November 25, 2008
    Publication date: December 15, 2011
    Inventors: ZhaoHai Qin, Yongqiang Ma, Wangcang Su, Lei Wang, Zheng Zhang, Bengbin Zhao, Jiangsheng Fang
  • Publication number: 20110136878
    Abstract: A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(=G1)-Q1 (wherein G1 and G2 represent an oxygen atom or the like, Q1 represents a phenyl group which may have a substituent, a heterocyclic group which may have a substituent, or the like), or the like, Q2 represents a phenyl group or the like, G3 represents an oxygen atom or the like, and R1 and R2 each independently represent a hydrogen atom, a C1-C6 alkyl group, or a group represented by -L-D, or the like (provided that at least either R1 or R2 represents a group represented by -L-D); as an active ingredient exhibits an excellent effect.
    Type: Application
    Filed: June 29, 2009
    Publication date: June 9, 2011
    Applicant: Mitsui Chemicals Agro., Inc.
    Inventors: Yumi Kobayashi, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Hidenori Daido, Yusuke Takahashi, Shinichi Banba
  • Publication number: 20110130340
    Abstract: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or detecting anti-cancer agents.
    Type: Application
    Filed: December 6, 2010
    Publication date: June 2, 2011
    Inventors: Craig B. Thompson, Wei-Xing Zong
  • Publication number: 20100196517
    Abstract: This invention generally relates to improvement of the body and skin appearance, for example enhancing the appearance of sagging, wrinkled, or cellulite-afflicted areas of the skin and body, through the local delivery of a nitric oxide donor, for example, using delivery vehicles such as lotions, creams, liquids, and/or transdermal patches. In some embodiments, a delivery vehicle containing a nitric oxide donor, for example, L-arginine (an important biological precursor) or its derivatives in a sufficient concentration to improve the appearance of a selected area of the body may be applied. In certain cases, one or more agents may also be included that aid in the transfer of the nitric oxide donor into the tissue, which may overcome the resistance to transfer into the skin. Non-limiting examples of suitable agents include agents able to create hostile biophysical environments, for instance, choline chloride, magnesium chloride, and/or sodium chloride.
    Type: Application
    Filed: April 15, 2010
    Publication date: August 5, 2010
    Applicant: Strategic Science & Technologies, LLC
    Inventor: Eric Thor Fossel
  • Publication number: 20090270509
    Abstract: This invention relates to compositions comprising carbon-based diazeniumdiolates that release nitric oxide (NO). The carbon-based diazeniumdiolated molecules release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated molecules, compositions comprising such molecules, methods of using such compositions, and devices employing such molecule compositions.
    Type: Application
    Filed: July 2, 2009
    Publication date: October 29, 2009
    Applicant: Noxilizer, Inc.
    Inventors: Ernst V. Arnold, Blaine G. Doletski, Robert E. Raulli
  • Publication number: 20090170951
    Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
    Type: Application
    Filed: March 23, 2007
    Publication date: July 2, 2009
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Yousef Al-Abed
  • Publication number: 20080287425
    Abstract: The present invention relates to a method for controlling chinch bugs comprising introducing to a locus where chinch bug control is needed or expected to be needed a composition comprising a nitroguanidine insecticide.
    Type: Application
    Filed: February 9, 2006
    Publication date: November 20, 2008
    Applicant: FMC CORPORATION
    Inventors: Kim Watson, Robert Herrick
  • Patent number: 6833478
    Abstract: A method is provided for enhancing the solubility of an ionizable compound in a lipophilic medium by admixing the compound with an effective solubility-enhancing amount of an N,N-dinitramide salt. The ionizable compound, upon ionization, gives rise to a biologically active cationic species that ionically associates with the N,N-dinitramide anion N(NO2)2− following admixture with the N,N-dinitramide salt. The biologically active cationic species may be a pharmacologically active cation, in which case the method is useful for enhancing the penetration of the blood-brain barrier by the pharmacologically active cation. In other embodiments, the ionizable compounds are medical imaging or diagnostic agents, or agricultural agents such as pesticides. Salts of biologically active cations and N,N-dinitramide ion are also provided as novel compositions of matter.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: December 21, 2004
    Assignee: SRI International
    Inventors: Jeffrey C. Bottaro, Mark A. Petrie, Paul E. Penwell, David C. Bomberger
  • Patent number: 6806292
    Abstract: The present invention relates to novel substituted imide derivatives of the general formula (I) in which R1 represents optionally substituted cycloalkyl, R2 represents optionally substituted alkyl or optionally substituted cycloalkyl, R3 represents alkyl, alkoxy, alkylthio, amino, alkylamino or dialkylamino and R4 represents cyano or nitro, and to processes for their preparation and to their use for controlling animal pests and as herbicides.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: October 19, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Jochem Riebel, Stefan Herrmann, Achim Hense, Ernst-Rudolf Gesing, Kristian Kather, Stefan Lehr, Wolfram Andersch, Mark Wilhelm Drewes, Dieter Feucht, Achim Harder
  • Patent number: 6638979
    Abstract: The present invention relates to novel imidamide derivatives of the formula (I) in which R, R1, R2 and R3 are each as defined in the description, to a process for their preparation and to their use for controlling animal pests, such as insects, arachnids and, in particular, nematodes.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: October 28, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Jochem Riebel, Peter Gerdes, Ernst-Rudolf F. Gesing, Achim Hense, Johannes Kanellakopulos, Kristian Kather, Rolf Kirsten, Stefan Lehr, Lothar Rohe, Katharina Voigt, Detleff Wollweber, Wolfram Andersch
  • Publication number: 20030119751
    Abstract: Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase.
    Type: Application
    Filed: June 24, 2002
    Publication date: June 26, 2003
    Inventors: Richard B. Silverman, Jung-Mi Hah, Jose Antonio Gomez Vidal
  • Patent number: 6583125
    Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: June 24, 2003
    Assignee: SuperGen, Inc.
    Inventor: Joseph Rubinfeld
  • Publication number: 20030100613
    Abstract: The present invention relates to novel substituted imide derivatives of the general formula (I) 1
    Type: Application
    Filed: July 26, 2002
    Publication date: May 29, 2003
    Inventors: Hans-Jochem Riebel, Stefan Herrmann, Achim Hense, Ernst-Rudolf Gesing, Kristian Kather, Stefan Lehr, Wolfram Andersch, Mark Wilhelm Drewes, Dieter Feucht, Achim Harder
  • Patent number: 6472400
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: October 29, 2002
    Assignee: University of Kansas Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • Patent number: 6291442
    Abstract: Disclosed herein is the discovery that an allosteric receptor site exists on the intracellular surface of Shaker class voltage-gated potassium ion channels that is distinct from the pore and is involved in regulating gating of the pore. A class of compounds has been identified that binds to this allosteric site and modulates the length of time the channel remains open. Based on these discoveries, novel methods of modulating the activity of Shaker class voltage-gated potassium ion channels and assays for determining which compounds are modulators of these ion channels are reported herein.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: September 18, 2001
    Assignee: The General Hospital Corporation
    Inventor: Gary I. Yellen
  • Patent number: 6287601
    Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: September 11, 2001
    Inventor: Meri Charmyne Russell
  • Patent number: 6281252
    Abstract: A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: August 28, 2001
    Assignee: GelTex Pharmaceutical, Inc.
    Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III
  • Patent number: 6231894
    Abstract: Paraquat has been found to accept electrons from nitric oxide synthase (NOS) whereupon the reduced paraquat generates toxic O2− and prevents NOS from giving electrons to arginine and thereby inhibits NO production. This is generalized for compounds with a redox potential greater than nitric oxide synthase. The compounds inhibit nitric oxide synthase and kill cells including NOS by generating O2− and also by depriving the cells of the NO which they need. Applications include treating paraquat-induced injury and pathologically proliferating cells (tumors, restenosis benign prostatic hypertrophy, pulmonary hypertension, infective pathogens).
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: May 15, 2001
    Assignees: Duke University, National Jewish Medical and Research Center, Cornell Research Foundation, Inc.
    Inventors: Jonathan S. Stamler, Brian J. Day, Steven S. Gross, Owen W. Griffith
  • Patent number: 6045827
    Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: April 4, 2000
    Assignee: Meri Charmyne Russell
    Inventor: Meri Charmyne Russell
  • Patent number: 5905086
    Abstract: N-(2-Hydroxyethyl)nicotinamide nitrate or its salt prevents or ameliorates anxiety neurosis or panic disorder, or the following anxiety. This compound or its salt has few side effects and exhibits immediate action.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: May 18, 1999
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Toshiro Miura
  • Patent number: 5840759
    Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: November 24, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
  • Patent number: 5837736
    Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: November 17, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
  • Patent number: 5814667
    Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: September 29, 1998
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
  • Patent number: 5714511
    Abstract: A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.
    Type: Grant
    Filed: July 31, 1995
    Date of Patent: February 3, 1998
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The University of Pittsburgh
    Inventors: Joseph E. Saavedra, Larry K. Keefer, Timothy R. Billiar
  • Patent number: 5650442
    Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: July 22, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
  • Patent number: 5382595
    Abstract: A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydroben or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: January 17, 1995
    Assignee: Eisai Co., Ltd.
    Inventors: Norio Minami, Fumihiro Ozaki, Keiji Ishibashi, Yasuhiro Kabasawa, Megumi Ikemori, Toshiaki Ogawa, Takanori Kawamura
  • Patent number: 5354771
    Abstract: Methods for treatment of free-radical-mediated tissue injury, particularly sepsis, are provided wherein compositions containing at least one keto analog of a branched-chain amino acid are administered. The composition is administered orally or parenterally, preferably in frequent or continuous dosages. Preferred forms of the keto analogs are their ornithine, arginine, or sodium salts.
    Type: Grant
    Filed: June 24, 1993
    Date of Patent: October 11, 1994
    Assignee: The Johns Hopkins University
    Inventor: MacKenzie Walser
  • Patent number: 5340837
    Abstract: Compounds of the formula ##STR1## wherein each of o and p, independently of the other, is 0, 1, 2, 3, 4 or 5, the radicals R.sub.1 being the same or different when o is greater than 1 and the radicals R.sub.2 being the same or different when p is greater than 1;each of R.sub.1 and R.sub.2, independently of the other, is C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, halogen, --NO.sub.2, --OH, C.sub.1 -C.sub.4 alkoxy, halo-C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, halo-C.sub.1 -C.sub.4 alkylthio, --O--S(.dbd.O)--R.sub.6, --O--S(.dbd.O).sub.2 --R.sub.6, phenoxy or --N(R.sub.11)SO.sub.2 R.sub.12 and/or two substituents R.sub.1 and/or two substituents R.sub.2 are, independently of one another, together --Y--Z--Y--;R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl or halo-C.sub.1 -C.sub.4 alkyl;R.sub.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, unsubstituted phenyl or naphthyl or mono- or di-substituted phenyl or naphthyl;R.sub.5 is --S--R.sub.7, --S(.dbd.O)--R.sub.7, --S(.dbd.O).
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: August 23, 1994
    Assignee: Ciba-Geigy Corporation
    Inventors: Roger G. Hall, Alfons Pascual, Odd Kristiansen
  • Patent number: 5039705
    Abstract: This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M.sup.+ is a pharmaceutically acceptable cation, wherein X is the valence of the cation.
    Type: Grant
    Filed: September 15, 1989
    Date of Patent: August 13, 1991
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Larry K. Keefer, David A. Wink, Tambra M. Dunams, Joseph A. Hrabie
  • Patent number: 5021429
    Abstract: Compounds of the general formula: ##STR1## and physiologically acceptable salts, and hydrates, N-oxides and bioprecursors of such compounds and such salts in whichR.sub.1 and R.sub.2, which may be the same or different, represent hydrogen or lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, or lower alkyl groups interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached form a heterocyclic ring which may contain the hetero functions --O-- and ##STR3## R.sub.3 represents hydrogen, lower alkyl, alkenyl or alkoxyalkyl; X represents --O--, --S-- or --CH.sub.2 -- or ##STR4## where R.sub.5 is hydrogen or lower alkyl; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.6 or .dbd.CHR.sub.7 ;in which R.sub.6 represents hydrogen, nitro, cyano, lower alkyl, aryl, arylsulphonyl or lower alkylsulphonyl; R.sub.
    Type: Grant
    Filed: December 22, 1986
    Date of Patent: June 4, 1991
    Assignee: Allen & Hansburys Limited
    Inventor: Michael Martin-Smith
  • Patent number: 4954526
    Abstract: A method of treating cardiovascular disorders in a mammal, by administering to said mammal an effective amount of a compound of the formula:[R--N(H)N(NO)O--].sub.y Xwherein R is loweralkyl, aryl, arylalkyl, or cycloalkyl, any of which R groups may be optionally substituted by one to three substituents selected from the group consisting of: halo, hydroxyl, alkoxy, amino, amido, formyl, carboxyl, or nitro; and wherein X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from loweralkyl, acyl or amido, and Y is 1 to 3 consistent with the valence of X. Pharmaceutical compositions containing the compounds are also provided.
    Type: Grant
    Filed: February 28, 1989
    Date of Patent: September 4, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Larry K. Keefer
  • Patent number: 4568694
    Abstract: Cystamine derivatives of the formula: ##STR1## [wherein n represents 2 or 3, R.sup.1 and R.sup.2 each represents a hydrogen atom, or an alkyl group optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, or represents a cycloalkyl or aryl group, and X.sup.1 represents a group selected from the formulae .dbd.N--CN, .dbd.N--NO.sub.2, .dbd.N--COR.sup.3, .dbd.N--COOR.sup.3, .dbd.N--NH--CONH.sub.2, .dbd.N--SO.sub.2 R.sup.3, .dbd.CH--NO.sub.2, .dbd.CH--SO.sub.2 R.sup.3, .dbd.C(CN).sub.2, .dbd.C(CN)COOR.sup.3 and .dbd.C(CN)CONH.sub.2 (wherein R.sup.3 represents an alkyl or aryl group), or R.sup.1 represents a hydrogen atom, R.sup.2 represents an alkyl group optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, or represents a cycloalkyl or aryl group and X.sup.1 represents an oxygen or sulphur atom] have been found to be useful in the promotion of the growth of non-human animals including birds.
    Type: Grant
    Filed: June 15, 1983
    Date of Patent: February 4, 1986
    Assignee: May & Baker Limited
    Inventors: Richard M. Griffin, Malcolm N. Palfreyman